Real-world survival outcomes of immunotherapy for advanced non-small cell lung cancer: A single-center retrospective review.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) is often diagnosed at an advanced stage. Clinical trials have demonstrated that first-line immunotherapy alone or in combination with chemotherapy improves overall survival. However, reports of survival outcomes in real-world settings are limited. We assessed survival in advanced NSCLC patients treated with immunotherapy alone or in combination with chemotherapy in first- or second-line at the Windsor Regional Cancer Program (WRCP) and compared it to existing literature.

Methods

We included patients diagnosed with stage IV NSCLC from January 2015 to December 2020 and treated with first-line chemoimmunotherapy (ChemoImmuno1), chemotherapy followed by immunotherapy (Chemo1), or immunotherapy followed by chemotherapy (Immno1) in our

SUBMITTER: Punchhi G 

PROVIDER: S-EPMC10864119 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature